{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T01:56:44Z","timestamp":1774922204639,"version":"3.50.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1016\/j.intimp.2010.12.012","type":"journal-article","created":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T09:27:08Z","timestamp":1293874028000},"page":"519-524","source":"Crossref","is-referenced-by-count":39,"title":["Clinical efficacy and immunological impact of tacrolimus in Chinese patients with generalized myasthenia gravis"],"prefix":"10.1016","volume":"11","author":[{"given":"C.-B.","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.-Q.","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-H.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.-Z.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.-G.","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2010.12.012_bb0005","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1056\/NEJM199406233302507","article-title":"Myasthenia gravis","volume":"330","author":"Drachman","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.intimp.2010.12.012_bb0010","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1196\/annals.1405.042","article-title":"CD4+ T cells and cytokines in the pathogenesis of acquired myasthenia gravis","volume":"1132","author":"Conti-Fine","year":"2008","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.intimp.2010.12.012_bb0015","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/ana.21536","article-title":"Novel complement inhibitor limits severity of experimentally myasthenia gravis","volume":"65","author":"Soltys","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1016\/j.intimp.2010.12.012_bb0020","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/(SICI)1097-4598(199705)20:5<543::AID-MUS2>3.0.CO;2-9","article-title":"Cytokines and the pathogenesis of myasthenia gravis","volume":"20","author":"Zhang","year":"1997","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.intimp.2010.12.012_bb0025","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1055\/s-2004-829593","article-title":"The epidemiology of myasthenia gravis","volume":"24","author":"Phillips","year":"2004","journal-title":"Semin Neurol"},{"key":"10.1016\/j.intimp.2010.12.012_bb0030","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","article-title":"Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity","volume":"8","author":"Meriggioli","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.intimp.2010.12.012_bb0035","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.nurt.2008.08.011","article-title":"Current and future standards in treatment of myasthenia gravis","volume":"5","author":"Gold","year":"2008","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.intimp.2010.12.012_bb0040","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/0167-5699(92)90111-J","article-title":"The mechanism of action of cyclosporin A and FK506","volume":"13","author":"Schreiber","year":"1992","journal-title":"Immunol Today"},{"key":"10.1016\/j.intimp.2010.12.012_bb0045","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/352803a0","article-title":"Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A","volume":"352","author":"Flanagan","year":"1991","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2010.12.012_bb0050","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1159\/000085833","article-title":"Efficacy of low-dose FK506 in the treatment of myasthenia gravis\u2014a randomized pilot study","volume":"53","author":"Nagane","year":"2005","journal-title":"Eur Neurol"},{"key":"10.1016\/j.intimp.2010.12.012_bb0055","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1212\/01.WNL.0000160392.32894.6D","article-title":"Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis","volume":"64","author":"Ponseti","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.intimp.2010.12.012_bb0060","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1136\/jnnp.2004.042176","article-title":"Long-term treatment of generalised myasthenia gravis with FK506 (tacrolimus)","volume":"76","author":"Konishi","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.intimp.2010.12.012_bb0065","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1185\/030079904125004385","article-title":"Low-dose tacrolimus treatment in thymectomised and steroid-dependent myasthenia gravis","volume":"20","author":"Kawaguchi","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.intimp.2010.12.012_bb0070","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0303-8467(03)00046-5","article-title":"Tacrolimus hydrate (FK506): therapeutic effects and selection of responders in the treatment of myasthenia gravis","volume":"106","author":"Wakata","year":"2003","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.intimp.2010.12.012_bb0075","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/mus.10472","article-title":"Clinical study of FK506 in patients with myasthenia gravis","volume":"28","author":"Konishi","year":"2003","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.intimp.2010.12.012_bb0080","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1054\/jocn.2001.0907","article-title":"Low-dose tacrolimus for intractable myasthenia gravis","volume":"9","author":"Yoshikawa","year":"2002","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.intimp.2010.12.012_bb0085","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jns.2006.03.010","article-title":"Long-term therapeutic efficacy and safety of low-dose tacrolimus (FK506) for myasthenia gravis","volume":"247","author":"Tada","year":"2006","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.intimp.2010.12.012_bb0090","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0887-8994(99)00112-5","article-title":"High-dose intravenous immunoglobulin therapy in juvenile myasthenia gravis","volume":"22","author":"Selcen","year":"2000","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.intimp.2010.12.012_bb0095","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0003-4975(00)01595-2","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America","volume":"70","author":"Jaretzki","year":"2000","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.intimp.2010.12.012_bb0100","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1212\/WNL.56.1.97","article-title":"Mycophenolate mofetil for myasthenia gravis: an open-label pilot study","volume":"56","author":"Ciafaloni","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.intimp.2010.12.012_bb0105","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","article-title":"Myasthenia gravis activities of daily living profile","volume":"52","author":"Wolfe","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.intimp.2010.12.012_bb0110","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1084\/jem.188.9.1679","article-title":"Human immunoglobulin (Ig)M+IgD+ peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells","volume":"188","author":"Klein","year":"1998","journal-title":"J Exp Med"},{"key":"10.1016\/j.intimp.2010.12.012_bb0115","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/nprot.2009.246","article-title":"Multiplexed immunophenotyping of human antigen-presenting cells in whole blood by polychromatic flow cytometry","volume":"5","author":"Fung","year":"2010","journal-title":"Nat Protoc"},{"key":"10.1016\/j.intimp.2010.12.012_bb0120","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1136\/ard.56.11.690","article-title":"Treatment of severe and difficult cases of systemic lupus erythematosus with tacrolimus. A report of three cases","volume":"56","author":"Duddridge","year":"1997","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.intimp.2010.12.012_bb0125","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1097\/01.mcg.0000139050.67178.be","article-title":"Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis","volume":"38","author":"Aqel","year":"2004","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.intimp.2010.12.012_bb0130","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000084648","article-title":"Management of severe refractory adult autoimmune enteropathy with infliximab and tacrolimus","volume":"71","author":"von Hahn","year":"2005","journal-title":"Digestion"},{"key":"10.1016\/j.intimp.2010.12.012_bb0135","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1006\/jaut.1996.0111","article-title":"FK506 prevents induction of rat experimental autoimmune myasthenia gravis","volume":"10","author":"Yoshikawa","year":"1997","journal-title":"J Autoimmun"},{"key":"10.1016\/j.intimp.2010.12.012_bb0140","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.clineuro.2004.07.013","article-title":"Benefits of FK506 (tacrolimus) for residual, cyclosporin- and prednisone-resistant myasthenia gravis: one-year follow-up of an open-label study","volume":"107","author":"Ponseti","year":"2005","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.intimp.2010.12.012_bb0145","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.braindev.2008.08.016","article-title":"Benefits of FK 506 for refractory eye symptoms in a young child with ocular myasthenia gravis","volume":"31","author":"Ishigaki","year":"2009","journal-title":"Brain Dev"},{"key":"10.1016\/j.intimp.2010.12.012_bb0150","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1196\/annals.1405.000","article-title":"Tacrolimus for myasthenia gravis: a clinical study of 212 patients","volume":"1132","author":"Ponseti","year":"2008","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.intimp.2010.12.012_bb0155","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2169\/internalmedicine.47.0513","article-title":"Long-term treatment of steroid-dependent myasthenia gravis patients with low-dose tacrolimus","volume":"47","author":"Nagaishi","year":"2008","journal-title":"Intern Med"},{"key":"10.1016\/j.intimp.2010.12.012_bb0160","doi-asserted-by":"crossref","first-page":"22992","DOI":"10.1016\/S0021-9258(19)49416-7","article-title":"The calcium release channel of sarcoplasmic reticulum is modulated by FK-506-binding protein. Dissociation and reconstitution of FKBP-12 to the calcium release channel of skeletal muscle sarcoplasmic reticulum","volume":"268","author":"Timerman","year":"1993","journal-title":"J Biol Chem"},{"key":"10.1016\/j.intimp.2010.12.012_bb0165","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1021\/bi048503v","article-title":"Differential control of glucocorticoid receptor hormone-binding function by tetratricopeptide repeat (TPR) proteins and the immunosuppressive ligand FK506","volume":"44","author":"Davies","year":"2005","journal-title":"Biochemistry"},{"key":"10.1016\/j.intimp.2010.12.012_bb0170","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1096\/fasebj.14.1.185","article-title":"A peptide vaccine that prevents experimental autoimmune myasthenia gravis by specifically blocking T cell help","volume":"14","author":"Araga","year":"2000","journal-title":"FASEB J"},{"key":"10.1016\/j.intimp.2010.12.012_bb0175","doi-asserted-by":"crossref","first-page":"158","DOI":"10.3988\/jcn.2007.3.3.158","article-title":"Myasthenia gravis appearing after thymectomy: a case report and review of the literature","volume":"3","author":"Kang","year":"2007","journal-title":"J Clin Neurol"},{"key":"10.1016\/j.intimp.2010.12.012_bb0180","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1212\/WNL.44.9.1732","article-title":"Treatment of myasthenia gravis with anti-CD4 antibody: improvement correlates to decreased T-cell autoreactivity","volume":"44","author":"Ahlberg","year":"1994","journal-title":"Neurology"},{"key":"10.1016\/j.intimp.2010.12.012_bb0185","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3109\/08916939908993860","article-title":"Cell-surface expression of lymphocyte activation markers in myasthenia gravis","volume":"31","author":"Ragheb","year":"1999","journal-title":"Autoimmunity"},{"key":"10.1016\/j.intimp.2010.12.012_bb0190","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.4049\/jimmunol.0800933","article-title":"B cell receptor and BAFF receptor signaling regulation of B cell homeostasis","volume":"183","author":"Khan","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.intimp.2010.12.012_bb0195","doi-asserted-by":"crossref","first-page":"5630","DOI":"10.4049\/jimmunol.0901100","article-title":"Absence of mature peripheral B cell populations in mice with concomitant defects in B cell receptor and BAFF-R signaling","volume":"183","author":"Hoek","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.intimp.2010.12.012_bb0200","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.clim.2007.10.001","article-title":"Decrease of CD4(+)CD25(high)Foxp3(+) regulatory T cells and elevation of CD19(+)BAFF-R(+) B cells and soluble ICAM-1 in myasthenia gravis","volume":"126","author":"Li","year":"2008","journal-title":"Clin Immunol"},{"key":"10.1016\/j.intimp.2010.12.012_bb0205","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jaci.2008.11.022","article-title":"Local release of B cell-activating factor of the TNF family after segmental allergen challenge of allergic subjects","volume":"123","author":"Kato","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.intimp.2010.12.012_bb0210","doi-asserted-by":"crossref","first-page":"122","DOI":"10.4161\/oxim.3.2.11149","article-title":"Release of B cell-activating factor of the TNF family in bronchoalveolar lavage from Beh\u00e7et's disease with pulmonary involvement","volume":"3","author":"Hamzaoui","year":"2010","journal-title":"Oxid Med Cell Longev"},{"key":"10.1016\/j.intimp.2010.12.012_bb0215","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jneuroim.2007.12.008","article-title":"Clinical efficacy and cytokine network-modulating effects of tacrolimus in myasthenia gravis","volume":"195","author":"Furukawa","year":"2008","journal-title":"J Neuroimmunol"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576910004157?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576910004157?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T19:39:31Z","timestamp":1637091571000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576910004157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["S1567576910004157"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2010.12.012","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4]]}}}